• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

DENOSUMAB Drug Record

  • Summary
  • Interactions
  • Claims
  • DENOSUMAB chembl:CHEMBL1237023 ApprovedAntineoplasticImmunotherapy

    Alternate Names:

    PROLIA
    DENOSUMAB
    AMG-162
    TK-006
    PROLIA, XGEVA
    TK006
    PROLIA, RANMARK XGEVA
    XGEVA
    drugbank:06643
    chemidplus:615258-40-7
    chembl:CHEMBL1237023
    rxcui:993449

    Drug Info:

    FDA Approval Giant cell tumor of the bone
    Drug Class Therapeutic Antibodies
    FDA Approval approved
    Drug Class monoclonal antibody
    Drug Indications antiosteoporotic agent
    Year of Approval 2010
    Drug Class osteoporosis prophylaxis
    (5 More Sources)

    Publications:

    Lipton et al., 2008, RANKL inhibition in the treatment of bone metastases., Curr Opin Support Palliat Care
    Westenfeld et al., 2006, Anti-RANKL therapy--implications for the bone-vascular-axis in CKD? Denosumab in post-menopausal women with low bone mineral density., Nephrol. Dial. Transplant.
    Nolan et al., 2016, RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers., Nat. Med.
  • DENOSUMAB   TNFSF11

    Interaction Score: 69.56

    Interaction Types & Directionality:
    antibody (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Notes
    Trial Name Denosumab
    Novel drug target Established target

    PMIDs:
    18685421 16702197


    Sources:
    TALC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial ChemblInteractions TEND TTD

  • DENOSUMAB   BRCA1

    Interaction Score: 0.64

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Emerging
    Approval Status Clinical Study
    Response Type not applicable

    PMIDs:
    27322743


    Sources:
    JAX-CKB

  • MyCancerGenome: DENOSUMAB

    • Version: 20-Jun-2017

    Alternate Names:
    XGEVA Trade Name

    Drug Info:
    Drug Class Therapeutic Antibodies
    FDA Approval Giant cell tumor of the bone

    Publications:

  • TEND: DENOSUMAB

    • Version: 01-August-2011

    Alternate Names:
    DENOSUMAB Primary Drug Name

    Drug Info:
    Drug Class osteoporosis prophylaxis
    Year of Approval 2010

    Publications:

  • TdgClinicalTrial: DENOSUMAB

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antiosteoporotic agent
    Drug Class monoclonal antibody
    FDA Approval approved

    Publications:

  • JAX-CKB: Denosumab

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Nolan et al., 2016, RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers., Nat. Med.

  • TTD: Denosumab

    • Version: 2020.06.01

    Alternate Names:
    D08WSY TTD Drug ID

    Drug Info:

    Publications:

  • TALC: DENOSUMAB

    • Version: 12-May-2016

    Alternate Names:
    DENOSUMAB Primary Drug Name
    DENOSUMAB Drug Generic Name
    XGEVA Drug Trade Name

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1237023

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL1237023

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

  • ClearityFoundationClinicalTrial: DENOSUMAB

    • Version: 15-June-2013

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21